Celgene

U.S. stocks were little changed as the second quarter comes to an end. Investors and traders are likely spending the last day of the quarter the same way they did to ring in the quarter: questioning the direction of the U.S. economy and wondering what is in store in the coming quarter. One...

U.S. stocks were mildly higher as the second quarter comes to an end on Monday, before the markets pause for the Fourth of July holiday. Economic data was light as investors showed little interest as consumer sentiment improved in June from May. Recommended: Will The Markets Be Bullied By The...

U.S. stocks were little changed the day after investors and traders were reassured by the Federal Reserve that interest rates will not rise in the near-term. The U.S. government reported that fewer Americans filed claims for jobless benefits in the previous week, partly helping the S&P 500...

U.S. stocks gained on Thursday despite the Commerce Department reporting that U.S. gross domestic product declined at a one percent annualized rate in the quarter. Analysts were expecting GDP to decline 0.4 percent. Pending home sales were below expectations but investors may have shrugged off...

While Amgen (NASDAQ: AMGN) saw a sizable dip in short interest between the April 30 and May 15 settlement dates, short sellers piled on Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC). Among other leading biotechs and emerging pharmaceuticals, gains in the number of their shares sold...

Biotech stocks have proved to be volatile this year, and short sellers piled on Incyte (NASDAQ: INCY) between the April 15 and April 30 settlement dates. Pharmacyclics (NASDAQ: PCYC) and Regeneron Pharmaceuticals (NASDAQ: REGN) also saw double-digit percentage increases in the number of their...

U.S. stocks declined as investors continue to follow the increasing tense situation in Ukraine as the markets pause for the weekend. Ukraine forces reportedly killed up to five pro-Russia rebels as the Russian military continues to conduct drills close to the Ukraine border. Additionally,...

U.S. stocks inched higher as Apple's strong earnings reported on Wednesday proved to be not enough to ease fears over an escalating tension between Russia and Ukraine. Reports surfaced of escalated troop movements in Ukraine while Russia began military drills near the Ukraine border. After...

The earnings crunch is underway. Highlights this week include scheduled quarterly reports from Amazon.com, Apple, Facebook, Netflix and Starbucks, which are all expected to post earnings growth, as well as from Ford, McDonald's and Microsoft, for which earnings declines are forecast. Here is a...

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates. But Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) were among those that bucked the...

U.S. stocks ended the week on a sour note as investors continue to sell many momentum names. Not helping the bull case was the much anticipated Jobs report number which failed to "wow" the market, coming in relatively in-line with expectations. The Dow suffered a triple digit point loss and...

U.S. stocks were slightly lower as positive labor market data clashed with fourth quarter GDP estimates that showed the economic expanded less than economists had expected. Major indices finished slightly lower as the Nasdaq index continues to see its losses fall sharper compared to the Dow and...

After largely shying away in the previous period, short sellers found renewed interest in many of the leading biotech and emerging pharmaceutical companies between the February 28 and March 14 settlement dates. But Celgene (NASDAQ: CELG), Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC...

U.S. stocks declined for the second straight session on little market-moving news. The Nasdaq index was hit harder than other major indices with investors and traders selling off otherwise solid performers like Facebook, Google, Tesla, Keurig Green Mountain and others. "These are all stocks...

Short interest in most of the leading biotech and emerging pharmaceutical companies declined between the February 14 and February 28 settlement dates. But Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) bucked that trend. Short interest in Gilead...